A Decade At The Top: Lupin MD On Listing Adjacencies, Creating Health Care Continuum

Promoters Don’t Intend Selling Stake

As family-led firms go through a churn in India, Lupin’s MD Nilesh Gupta speaks about adding value via adjacencies to the legacy business, building digital interfaces and a healthcare continuum for patients. In an interview with Scrip, he also emphasized Lupin promoters are neither interested in selling their own stake nor in acquiring that of Cipla’s promoters.

Lupin Ltd Managing Director Nilesh Gupta
Lupin MD Nilesh Gupta On Moving Beyond Drugs To Create A Healthcare Continuum • Source: Lupin Ltd

"It is up to us to live up to the legacy that was left for us, and to leave a legacy that is worthy of our children and of future generations,” said Christine Gregoire, American politician and governor of State of Washington.

At a time when founding families of several pharmaceutical companies firms in India, including JB Chemicals & Pharmaceuticals Ltd

When Lupin’s founder chairman Desh Bandhu Gupta, or DB as he was known, passed away in 2017, he left a business worth over $2bn for son Nilesh and four daughters. It’s now a decade since eldest sibling Vinita Gupta took over as CEO and Nilesh Gupta as managing director in September 2013

More from C-Suite Speaks

More from Leadership